Phase 2 N=47 Alemtuzumab to Treat Severe Aplastic Anemia
Severe Aplastic Anemia, Refractory · Severe Aplastic Anemia, Relapse
Primary: Number of Participants With Hematological Response at 6 Months — 0; 18 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Assessment of Mealtime Bolus Insulin Behavior
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM — 19.3 Days per month
N/A N=209 Cohort Study on A Following-up System of Native Arteriovenous Fistulae
Arteriovenous Fistulae
Primary: Number of Participants With Fistula Failure — 11; 15 Participants
Phase 2 N=117 Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 50.0; 35.6 Percentage of participants
N/A N=88 Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT
Persistent Post-surgical Pain · Acceptance and Commitment Therapy · Substance Use Disorder
Primary: Percent of Veterans Willing and Able to Receive the ACT Intervention. — 80; 100 percent
N/A N=268 Evaluation of the QuantiFERON-TB Test.
Tuberculosis
Primary: Clinical Specificity of the CST001 Assay as Measured by the Number of Correctly Identified Actual Negatives — 49; 208 Participants
Phase 3 N=1,899 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
Myocardial Infarction
Primary: Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. — 116; 135…
N/A N=114 A Proof of Concept Study to Investigate the Effect of a New Treatment in Patient With Chronic Pain
Peripheral Neuropathies · Osteoarthritis
Primary: Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment — 0.54; 0.95 score on…
Phase 1 N=21 Palliative Thoracic Radiotherapy Plus BKM120
Carcinoma, Non-Small-Cell Lung
Primary: Dose Escalation Analysis: Number of DLTs Observed in Evaluable Patients — 0; 0; 0 Participants
N/A N=61 Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy
Primary: Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS]) — 5.9; 11.8; 11.5; 12.8 units on a…
Phase 2 N=123 Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 24.1; 23.6; 13.9; 16.9 mmHg — p=0.001
Phase 1 N=56 A FIH Study to Investigate the Safety, Tolerability and PK of P218
Malaria
Primary: Safety and Tolerability of P218: Incidence, Severity and Relationship to the Investigational Product of Observed and Self-reported Adverse Events — 0; 0; 2; 1 Participants
N/A N=65 Snack Food Reinforcement in Obese and Non-obese Women
Obesity
Primary: Number of Responses Made by Clicking a Mouse Button for Food — 397.63; 288.36; 429.5; 213.2 Number of button presses
N/A N=1,334 Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Coronary Artery Disease · Atherosclerosis, Coronary · Myocardial Ischemia
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation — 6.32; 8.90 Percentage of participants
Phase 1 N=33 Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
Type 1 Diabetes Mellitus · Maturity-Onset Diabetes of the Young, Type 2 · MODY2
Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min